Describe the project’s focus on Casgevy (exagamglogene autotemcel), a gene therapy used to treat sickle cell disease in patients with recurrent vaso-occlusive crises who are 12 years of age and older.

Describe the project’s focus on Casgevy (exagamglogene autotemcel), a gene therapy used to treat sickle cell disease in patients with recurrent vaso-occlusive crises who are 12 years of age and older. It involves an autologous genome-edited hematopoietic stem cell-based approach. The therapy requires patients to undergo stem cell mobilization and apheresis, followed by a specific dosing based on body weight and full myeloablative conditioning before the Casgevy infusion. The document details indications, dosage, administration methods, contraindications, warnings, adverse reactions, and clinical pharmacology, providing comprehensive information about this innovative treatment. Check the other pdf file to create the exact style of the newsletter

Last Completed Projects